Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Thursday

Key Points

• Trevi Therapeutics is set to release its Q2 2025 earnings before market opens on August 7, with analysts predicting a loss of ($0.10) per share.
• The company reported a loss of ($0.09) EPS in the previous quarter, surpassing expectations of a loss of ($0.13) EPS.
• Institutional investors own 95.76% of the company's stock, with notable increases in stakes from firms such as Millennium Management LLC, which boosted its holdings by 356.3%.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Trevi Therapeutics to post earnings of ($0.10) per share for the quarter.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04. On average, analysts expect Trevi Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Price Performance

TRVI traded up $0.04 on Friday, hitting $7.45. The company had a trading volume of 384,578 shares, compared to its average volume of 1,851,403. The company's fifty day moving average price is $6.45 and its 200 day moving average price is $5.76. Trevi Therapeutics has a 1-year low of $2.36 and a 1-year high of $8.11. The stock has a market cap of $873.83 million, a price-to-earnings ratio of -16.56 and a beta of 0.46.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Trevi Therapeutics during the first quarter worth $52,000. AQR Capital Management LLC grew its position in Trevi Therapeutics by 20.4% during the first quarter. AQR Capital Management LLC now owns 27,720 shares of the company's stock worth $174,000 after buying an additional 4,688 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company's stock worth $278,000 after buying an additional 10,445 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of Trevi Therapeutics by 356.3% in the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company's stock worth $5,178,000 after purchasing an additional 642,830 shares in the last quarter. Institutional investors own 95.76% of the company's stock.

Analyst Upgrades and Downgrades

TRVI has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price target on the stock. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. D. Boral Capital reissued a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Needham & Company LLC reissued a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research report on Tuesday, May 20th. Finally, HC Wainwright began coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $20.88.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.